STI571 (Gleevec) as a paradigm for cancer therapy - PubMed (original) (raw)
Review
STI571 (Gleevec) as a paradigm for cancer therapy
Brian J Druker. Trends Mol Med. 2002.
Abstract
STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.
Similar articles
- Perspectives on the development of a molecularly targeted agent.
Druker BJ. Druker BJ. Cancer Cell. 2002 Feb;1(1):31-6. doi: 10.1016/s1535-6108(02)00025-9. Cancer Cell. 2002. PMID: 12086885 Review. - STI571: a paradigm of new agents for cancer therapeutics.
Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. Mauro MJ, et al. J Clin Oncol. 2002 Jan 1;20(1):325-34. doi: 10.1200/JCO.2002.20.1.325. J Clin Oncol. 2002. PMID: 11773186 Review. - The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. Curr Cancer Drug Targets. 2001 May;1(1):49-57. doi: 10.2174/1568009013334250. Curr Cancer Drug Targets. 2001. PMID: 12188891 Review. - STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. Lancet Oncol. 2000 Dec;1:207-11. doi: 10.1016/s1470-2045(00)00149-2. Lancet Oncol. 2000. PMID: 11905636 Review. - Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. J Intern Med. 2001 Jul;250(1):3-9. doi: 10.1046/j.1365-2796.2001.00823.x. J Intern Med. 2001. PMID: 11454136 Review.
Cited by
- Fast and sensitive validation of fusion transcripts in whole-genome sequencing data.
Hafstað V, Häkkinen J, Persson H. Hafstað V, et al. BMC Bioinformatics. 2023 Sep 23;24(1):359. doi: 10.1186/s12859-023-05489-5. BMC Bioinformatics. 2023. PMID: 37741966 Free PMC article. - Drug delivery targets and strategies to address mast cell diseases.
Rische CH, Thames AN, Krier-Burris RA, O'Sullivan JA, Bochner BS, Scott EA. Rische CH, et al. Expert Opin Drug Deliv. 2023 Feb;20(2):205-222. doi: 10.1080/17425247.2023.2166926. Epub 2023 Jan 29. Expert Opin Drug Deliv. 2023. PMID: 36629456 Free PMC article. Review. - Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights.
Eldehna WM, Maklad RM, Almahli H, Al-Warhi T, Elkaeed EB, Abourehab MAS, Abdel-Aziz HA, El Kerdawy AM. Eldehna WM, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1227-1240. doi: 10.1080/14756366.2022.2062337. J Enzyme Inhib Med Chem. 2022. PMID: 35470754 Free PMC article. - Synthesis and biological evaluation of new derivatives of thieno-thiazole and dihydrothiazolo-thiazole scaffolds integrated with a pyrazoline nucleus as anticancer and multi-targeting kinase inhibitors.
Othman IMM, Alamshany ZM, Tashkandi NY, Gad-Elkareem MAM, Abd El-Karim SS, Nossier ES. Othman IMM, et al. RSC Adv. 2021 Dec 22;12(1):561-577. doi: 10.1039/d1ra08055e. eCollection 2021 Dec 20. RSC Adv. 2021. PMID: 35424523 Free PMC article. - Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors.
Yan L, Wang Q, Liu L, Le Y. Yan L, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):832-843. doi: 10.1080/14756366.2022.2046567. J Enzyme Inhib Med Chem. 2022. PMID: 35260020 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous